Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-655

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 655 52 Master Bottle Label Approval Rev B 05 21)

This is a package of Valsartan and Hydrochlorothiazide Tablets, USP with 320mg and 25mg doses. The package contains 30 tablets and is for prescription-only use. The dosage and package insert should be followed. The tablets should be stored at 7-25°C (68°F), and excursions are permitted to 15°-30°C (59°-86°F). The drug should be kept in the original container, protected from moisture, and out of children's reach. The drug's details, such as its NDC, LCN#, Rev. B, GTIN, S/N, EXP and LOT are provided on the package. The drug is repackaged by Northwind Pharmaceuticals under the Macleods Pharma USA, Inc., lot number, 33342-078-xx.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

This is a chart displaying blood pressure readings for a clinical trial. The medication being tested is Valsartan HCT at a dose of 320/25 mg. The chart displays the average blood pressure readings at each level from 140 to 180 mmHg. There is also a placebo group included in the trial.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

This is a table showing the baseline diastolic blood pressure (DBP) readings of a group of patients before treatment. The data includes four treatment options: oral medications containing 320 mg of valsartan, oral medications containing 320 mg of valsartan in combination with 25 mg of hydrochlorothiazide, oral medications containing only 25 mg of hydrochlorothiazide, and placebo. The target DBP for treatment is less than 90 mmHg.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

This is a table showing the different medications and dosages used in a medical study. It includes Valsartan and Hydrochlorothiazide among others. The last row shows the baseline SBP (Systolic Blood Pressure) measured in mmHg.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

This appears to be a table that shows baseline diastolic blood pressure (DBP) readings in mmHg for different medications, including Valsartan HCT, Valsartan, Hydrochlorothiazide, and a placebo group. The DBP readings range from 95 to 105 mmHg.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.